Osaka, Japan

Hirotaka Kurebayashi

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 44(Granted Patents)


Location History:

  • Osaka, JP (2016 - 2024)
  • Minoh, JP (2022 - 2024)

Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Hirotaka Kurebayashi: Innovator in Pharmaceutical Compounds

Introduction

Hirotaka Kurebayashi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on innovative compounds that have the potential to treat various medical conditions.

Latest Patents

Kurebayashi's latest patents include advancements in carboxylic acid compounds. These compounds are designed for pharmaceutical applications, particularly in treating allergic diseases, autoimmune diseases, viral diseases, and cancer. Another notable patent involves CDK9 inhibitors and their polymorphs, which are crucial for cancer treatment. These patents not only detail the compounds but also the methods for their preparation and use in pharmaceutical compositions.

Career Highlights

Throughout his career, Kurebayashi has worked with reputable companies such as Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Oncology, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical sector.

Collaborations

Kurebayashi has collaborated with notable colleagues, including Seiji Hori and Futoshi Hasegawa. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Hirotaka Kurebayashi is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact the treatment of various diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…